GlassScriptPhysician profile
Kyla A Ingram
NPI 1427697069
$5,134.09
in general payments reported to CMS, 2019-2025
27 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,006 · 2022: $1,150 · 2023: $695 · 2024: $708 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.53 |
| Education | $382.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,348.30 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $514.20 | 2021-2025 | |
| Grifols USA, LLC | $443.67 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $414.36 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $370.27 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Glaxosmithkline, LLC. | $307.83 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $276.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $274.88 | 2021-2025 | Dupixent |
| Amgen INC. | $195.45 | 2022-2025 | |
| Incyte Corporation | $160.60 | 2021-2023 | Opzelura |
| Csl Behring | $145.89 | 2022-2025 | Hizentra |
| Genentech, INC. | $80.03 | 2021 | |
| Biocryst US Sales Co., LLC | $72.23 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $66.88 | 2021-2022 | |
| Pharming Healthcare, INC. | $59.84 | 2022-2025 | Ruconest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.12 | 2025 | |
| Leo Pharma INC. | $57.01 | 2023-2025 | Adbry |
| Lilly USA, LLC | $56.83 | 2025 | Taltz, Ebglyss |
| Horizon Therapeutics Plc | $45.28 | 2021-2022 | |
| Galderma Laboratories, L.P. | $40.13 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $28.04 | 2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $26.98 | 2021 | |
| Alk-Abello, INC | $26.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.01 | 2025 | Voquezna |
| Octapharma USA, INC. | $21.58 | 2023 | Octagam Immune Globulin (Human) |
| Ars Pharmaceuticals Operations, INC. | $15.72 | 2025 | Neffy |
| Genentech USA, INC. | $3.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.